Stryker: The big player in robot-assisted ortho surgeryStryker (NYSE:SYK) saw its second-quarter sales slashed by a quarter amid the COVID-19 pandemic, but the company’s Mako robotic systems for knee and hip surgeries remain a bright spot. Stryker is arguably the dominant player in the robotic ortho surgery space, with the company passing the 1,000 mark for Mako installations.
“The lead that we have in robotics is clear, and it’s continuing, and it’s a really a global thing. We have over 28 countries now that have a Mako robot, and that growth will continue long into the future,” CEO Kevin Lobo said on Sept. 15 during a virtual healthcare conference held by Morgan Stanley.
Mako has proven to be a major growth engine for Stryker as health providers buy all of the tools and accessories around the system.
Stryker’s $500 million buyout of Mobius Imaging and its Cardan Robotics subsidiary in 2019 could provide it an avenue to compete against Medtronic in the robotic spine surgery space, though Lobo during the Morgan Stanley conference said the other option would be to come out with a more advanced option through Mako.